Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | NAAA | Q02083 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823192 | 0.91 | CYP17A1 (0.47) | CYP17A1TDP2PTGS2NAAAPTGS1 | |
| SCHEMBL12735633 | 0.91 | CYP17A1 (0.47) | CYP17A1TDP2PTGS2NAAAPTGS1 | |
| SCHEMBL10301950 | 0.90 | CYP17A1 (0.51) | CYP17A1PTGS2NAAAFFAR1ERN1 | |
| SCHEMBL12735563 | 0.89 | FYN (0.39) | FYNMEN1ALDH1A1KMT2AERN1 | |
| SCHEMBL12740101 | 0.89 | FYN (0.39) | FYNMEN1ALDH1A1KMT2AERN1 | |
| SCHEMBL12735651 | 0.88 | NAAA (0.40) | CYP17A1FYNKIF11PTGS2NAAA | |
| SCHEMBL12738888 | 0.88 | CYP17A1 (0.44) | CYP17A1FYNTDP2PTGS2NAAA | |
| SCHEMBL12740140 | 0.87 | CYP17A1 (0.44) | CYP17A1FYNPTGS2PTGS1ALDH1A1 | |
| SCHEMBL12735639 | 0.87 | RARB (0.46) | CYP17A1TDP2PTGS2NAAAPTGS1 | |
| SCHEMBL10303004 | 0.86 | CYP17A1 (0.55) | CYP17A1TDP2NAAAFFAR1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | CYP17A1 1283/4885FYN 211/4885TDP2 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.